跳至主要内容
临床试验/NCT02191475
NCT02191475Unknown2 期

Tigecycline (Hai Zheng Li Xing®) Combined With Piperacillin/Tazobactam (Tazocin ®) Empirical Treatment of Severe Sepsis and Septic Shock in Patients With Abdominal Infection

Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
100
试验地点
1
主要终点
Efficacy of treatment between Tigecycline plus tazocin and classic anti infection method

研究概览

简要总结

Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme, compared with the classical scheme, evaluate its efficacy, safety index.

详细描述

Tigecycline as representative glycylcycline antibiotics, has wide antibacterial spectrum and strong antibacterial activity, tigecycline in almost all of the gram positive bacteria and most gram negative bacteria and atypical pathogens, anaerobic bacteria are very good antibacterial activity except Pseudomonas aeruginosa, Proteus. Safety on organ function, in patients with renal insufficiency or in dialysis patients, no dose adjustment is required application of tigecycline, mild to moderate hepatic insufficiency patients do not need to adjust the dose of tigecycline. Piperacillin / tazobactam also is a broad spectrum, potent antibiotics, especially strong bactericidal activity against Pseudomonas aeruginosa, including resistant enzyme producing gram negative bacilli, in accordance with its pharmacokinetic pharmacodynamic characteristics of prolonged infusion time can obtain a stronger bactericidal activity. These two potent drugs have broad antimicrobial spectrum, strong bactericidal activity, and provide for the treatment of severe sepsis and septic shock a new choice in antibiotic selection, to a certain extent reduces the resistance pressure, and have more clinical safety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be consistent with severe sepsis and septic shock diagnosis standards
  • Age above 18 years old, is expected in more than 5 days in ICU
  • APACHEⅡ score>15
  • By the patients themselves or their authorized person agreed to participate in the clinical trial and signed the informed consent

排除标准

  • Allergic to penicillin, or of tigecycline allergic patients
  • Patients with abnormal liver function is severe
  • Be pregnant or lactating women
  • Be not signed the informed consent of patients
  • Any can be expected to increase patient risk or other factors can interfere with the results of a clinical trial

研究组 & 干预措施

glycopeptide plus carbapenem

Active Comparator

The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.

干预措施: glycopeptide plus carbapenem (Drug)

Haizheng Li Xing ® plus tazocin ®

Experimental

Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.

干预措施: Haizheng Li Xing ® plus tazocin ® (Drug)

结局指标

主要结局

Efficacy of treatment between Tigecycline plus tazocin and classic anti infection method

时间窗: 2 weeks

Two groups of patients were assessed anti infection treatment effect per day. Including: temperature, procalcitonin, blood routine, liver and kidney function, bacteriological evidence, hemodynamics Effects of Haizheng Li Xing ® combined with tazocin ® in clinical treatment is not inferior to the classical antibiotics scheme

次要结局

  • Successful rate between two groups with abnormal renal function and liver function abnormalities which should adjust dose of drugs(2 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验